NCT05188508 2026-03-06Pembrolizumab, Olaparib, and Temozolomide for People With GliomaMemorial Sloan Kettering Cancer CenterPhase 2 Recruiting57 enrolled
NCT03212274 2026-02-19Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 MutationsNational Cancer Institute (NCI)Phase 2 Active not recruiting89 enrolled